-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program
-
-
-
-
-
-
-
Mira Pharma (MIRA) Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
-
-
-
-
-
-
-
Esperion (ESPR) and Otsuka Report Bempedoic Acid Met Primary Endpoint in Phase 3 Trial
-
-
-
-
-
-
-
US FDA approves Amgen drug for small cell lung cancer
-
-
-
-
-
-
-
AxoGen (AXGN) Initiates Rolling Submission of BLA for Avance Nerve Graft
-
-
-
-
-
-
-
Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
-
-
-
-
-
-
-
Lumos Pharma (LUMO) Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
-
67,107 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.